


We claim:

1. A compound of Formula I,



5

wherein

- 10 A is a Met-AP2 inhibitory core;

W is O or NR₂;

R₁ and R₂ are each, independently, hydrogen or alkyl;

X is alkylene or substituted alkylene;

n is 0 or 1;

- 15 R₃ and R₄ are each, independently, hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; or R₃ and R₄, together with the carbon atom to which they are attached, form a carbocyclic or heterocyclic group; or R₃ and R₄ together form an alkylene group;

Z is -C(O)- or alkylene-C(O)-; and

- 20 P is a peptide comprising from 1 to about 100 amino acid residues attached at its amino terminus to Z or a group OR₅ or N(R₆)R₇, wherein

R₅, R₆ and R₇ are each, independently, hydrogen, alkyl, substituted alkyl, azacycloalkyl or substituted azacycloalkyl; or R₆ and R₇, together with the nitrogen atom to which they are attached, form a substituted or unsubstituted heterocyclic ring

- 25 structure;

or

Z is -O-, -NR₈-, alkylene-O- or alkylene-NR₈-, where R₈ is hydrogen or alkyl; and

P is hydrogen, alkyl or a peptide consisting of from 1 to about 100 amino acid residues attached at its carboxy terminus to Z.

30


2. The compound of claim 1, wherein at least one of R₁, R₃ and R₄ is a substituted or unsubstituted alkyl group.

3. The compound of claim 2, wherein at least one of R_1 , R_3 and R_4 is a substituted or unsubstituted normal, branched or cyclic C_1 - C_6 alkyl group.
- 5 4. The compound of claim 3, wherein at least one of R_1 , R_3 and R_4 is a normal or branched C_1 - C_4 alkyl group.
5. The compound of claim 1, wherein one of R_3 and R_4 is a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or
10 unsubstituted heteroarylalkyl group, or a substituted or unsubstituted aryl alkyl group.
6. The compound of claim 5, wherein one of R_3 and R_4 is selected from the group consisting of phenyl, naphthyl, indolyl, imidazolyl, pyridyl, benzyl, naphthylmethyl, indolylmethyl, imidazolylmethyl and pyridylmethyl.
15
7. The compound of claim 1, wherein n is 1 and X is C_1 - C_6 -alkylene.
8. The compound of claim 7, wherein X is methylene or ethylene.
- 20 9. The compound of claim 1, wherein Z is C_1 - C_6 -alkylene- $C(O)$ -.
10. The compound of claim 9, wherein Z is methylene- $C(O)$ - or ethylene- $C(O)$ -.
11. The compound of claim 1, wherein at least one of R_6 and R_7 is alkyl, substituted
25 alkyl, substituted or unsubstituted azacycloalkyl or substituted or unsubstituted azacycloalkyl.
12. The compound of claim 11, wherein at least one of R_6 and R_7 is an azacycloalkyl group having an N-alkyl substituent.
30
13. The compound of claim 12, wherein the N-alkyl substituent is a C_1 - C_4 -alkyl group.
14. The compound of claim 13, wherein the N-alkyl substituent is a methyl group.
35
15. The compound of claim 1, wherein R_6 and R_7 , together with the nitrogen atom to which they are attached, form a substituted or unsubstituted five or six-membered aza- or diazacycloalkyl group.


- 5


- 10

19. The compound of claim 1, wherein P is NH₂ or one of the groups shown below:




- 15





20. A compound of Formula XV,

5



(XV)

wherein

10 A is a MetAP-2 inhibitory core;

W is O or NR;

each R is, independently, hydrogen or alkyl;

Z is $-\text{C}(\text{O})-$ or $-\text{alkylene}-\text{C}(\text{O})-$;

P is NHR, OR or a peptide consisting of one to about one hundred amino acid residues

15 connected at the N-terminus to Z;

Q is hydrogen, linear, branched or cyclic alkyl or aryl, provided that when P is $-\text{OR}$, Q is not hydrogen;

or

Z is $-\text{alkylene}-\text{O}-$ or $-\text{alkylene}-\text{N}(\text{R})-$;

20 P is hydrogen or a peptide consisting of from one to about one hundred amino acid residues connected to Z at the carboxyl terminus;

Q is hydrogen, linear, branched or cyclic alkyl or aryl, provided that when P is hydrogen, Q is not hydrogen;

and pharmaceutically acceptable salts thereof.

25

21. The compound of claim 20, wherein Z is $-\text{C}(\text{O})-$ or $\text{C}_1\text{-C}_4\text{-alkylene}-\text{C}(\text{O})-$.

22. The compound of claim 21, wherein Z is -C(O)- or C₁-C₂-alkylene-C(O)-.

23. The compound of claim 21, wherein Q is linear, branched or cyclic C₁-C₆-alkyl, phenyl or naphthyl.

5

24. The compound of claim 23, wherein Q is isopropyl, phenyl or cyclohexyl.

25. The compound of claim 1, wherein Z is C₁-C₆-alkylene-O- or C₁-C₆-alkylene-NR-.

10

26. The compound of claim 25, wherein Z is C₁-C₄-alkylene-O- or C₁-C₄-alkylene-NH-.

15

27. The compound of claim 26, wherein Z is C₁-C₂-alkylene-O- or C₁-C₂-alkylene-NH.

28. The compound of claim 25, wherein Q is linear, branched or cyclic C₁-C₆-alkyl, phenyl or naphthyl.

20

29. The compound of claim 28, wherein Q is isopropyl, phenyl or cyclohexyl.

25

30. The compound of claim 20, wherein each R is, independently, hydrogen or linear, branched or cyclic C₁-C₆-alkyl.

31. The compound of claim 30, wherein each R is, independently, hydrogen or linear or branched C₁-C₄-alkyl.


30

32. The compound of claim 31, wherein each R is, independently, hydrogen or methyl.

33. The compound of claim 32, wherein each R is hydrogen.

35


34. The compound of claim 20, wherein A is of Formula II,




(II)

wherein


- 5 R_1 is hydrogen or alkoxy;
 R_2 is hydrogen or hydroxy;
 R_3 is hydrogen or alkyl; and
 D is linear or branched alkyl or arylalkyl; or D is of the structure




- 10 35. The compound of claim 34, wherein R_1 is C_1 - C_4 -alkoxy.
36. The compound of claim 35, wherein R_1 is methoxy.
37. The compound of claim 34, wherein R_3 is hydrogen or C_1 - C_4 -alkyl.
- 15 38. The compound of claim 37, wherein R_3 is methyl.
39. The compound of claim 34, wherein D is linear, branched or cyclic C_1 - C_6 -alkyl; or aryl- C_1 - C_4 -alkyl.
- 20 40. The compound of claim 20, wherein A is selected from the group consisting of




(IV)




(V)




(VI)



(VII)



(VIII)



(IX)


5

Wherein

- 10 p is an integer from 0 to 10;
 R₁ is hydrogen, -OH or C₁-C₄-alkoxy;
 X is a leaving group; and

R₂ is H, OH, amino, C₁-C₄-alkylamino or di(C₁-C₄-alkyl)amino).

41. The compound of claim 40, wherein A is of the formula



5

42. The compound of claim 20, wherein P comprises from 1 to about 20 amino acid residues.

10 43. The compound of claim 42, wherein P comprises an amino acid sequence which is a substrate for a matrix metalloprotease.

44. The compound of claim 43, wherein the matrix metalloprotease is selected from the group consisting of MMP-2, MMP-1, MMP-3, MMP-7, MMP-8, MMP-9,
15 MMP-12, MMP-13 and MMP-26.


45. The compound of claim 44, wherein the matrix metalloprotease is MMP-2 or MMP-9.

20 46. The compound of claim 45, wherein P comprises the sequence -Pro-Leu-Gly-Xaa-, wherein Xaa is a naturally occurring amino acid residue.

47. The compound of claim 46, wherein P comprises the a sequence selected from the group consisting of Pro-Cha-Gly-Cys(Me)-His (SEQ ID NO:2); Pro-Gln-Gly-Ile-Ala-Gly-Gln-D-Arg (SEQ ID NO:3); Pro-Gln-Gly-Ile-Ala-Gly-Trp (SEQ ID NO:4);
25 Pro-Leu-Gly-Cys(Me)-His-Ala-D-Arg (SEQ ID NO:5); Pro-Leu-Gly-Met-Trp-Ser-Arg (SEQ ID NO:35); Pro-Leu-Gly-Leu-Trp-Ala-D-Arg (SEQ ID NO:6); Pro-Leu-Ala-Leu-Trp-Ala-Arg (SEQ ID NO:7); Pro-Leu-Ala-Leu-Trp-Ala-Arg (SEQ ID NO:8); Pro-Leu-Ala-Tyr-Trp-Ala-Arg (SEQ ID NO:9); Pro-Tyr-Ala-Tyr-Trp-Met-Arg (SEQ ID NO:10);
30 Pro-Cha-Gly-Nva-His-Ala (SEQ ID NO:11); Pro-Leu-Ala-Nva (SEQ ID NO:12); Pro-Leu-Gly-Leu (SEQ ID NO:13); Pro-Leu-Gly-Ala (SEQ ID NO:14); Arg-Pro-Leu-Ala-Leu-Trp-Arg-Ser (SEQ ID NO:15); Pro-Cha-Ala-Abu-Cys(Me)-His-Ala (SEQ ID NO:16); Pro-Cha-Ala-Gly-Cys(Me)-His-Ala (SEQ ID NO:17); Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu (SEQ ID NO:18); Pro-Lys-Pro-Leu-Ala-Leu (SEQ ID NO:19); Arg-

Pro-Lys-Pro-Tyr-Ala-Nva-Trp-Met (SEQ ID NO:20); Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg (SEQ ID NO:21); Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg (SEQ ID NO:22); and Arg-Pro-Lys-Pro-Leu-Ala-Nva-Trp (SEQ ID NO:23).

- 5 48. A compound of the formula



wherein

- 10 W is O or NR;
 each R is, independently hydrogen or a C₁-C₄-alkyl;
 Q is hydrogen; linear, branched or cyclic C₁-C₆-alkyl; or aryl;
 R₁ is hydroxy, C₁-C₄-alkoxy or halogen;
 Z is -C(O)- or C₁-C₄-alkylene;
 15 P is NHR, OR, or a peptide comprising 1 to 100 amino acid residues attached to Z at the N-terminus; or
 Z is alkylene-O or alkylene-NR; and
 P is hydrogen or peptide comprising 1 to 100 amino acid residues attached to Z at the C-terminus;
 20 or a pharmaceutically acceptable salt thereof; provided that when P is hydrogen, NHR or OR, Q is not hydrogen.

49. The compound of claim 48, wherein

- W is O or NH;
 25 Z is alkylene-O or alkylene-NH;
 Q is isopropyl;
 R₁ is methoxy; and
 P comprises from 1 to 15 amino acid residues.

30 50. The compound of claim 49, wherein

- W is O; and
 P comprises 10 or fewer amino acid residues.

51. The compound of claim 48, wherein P comprises from 1 to about 20 amino acid residues.

52. The compound of claim 51, wherein P comprises an amino acid sequence which is a substrate for a matrix metalloprotease.

53. The compound of claim 52, wherein the matrix metalloprotease is selected from the group consisting of MMP-2, MMP-1, MMP-3, MMP-7, MMP-8, MMP-9, MMP-12, MMP-13 and MMP-26.

54. The compound of claim 53, wherein the matrix metalloprotease is MMP-2 or MMP-9.

55. The compound of claim 54, wherein P comprises the sequence -Pro-Leu-Gly-Xaa-, wherein Xaa is a naturally occurring amino acid residue.

56. The compound of claim 55, wherein P comprises the a sequence selected from the group consisting of Pro-Cha-Gly-Cys(Me)-His (SEQ ID NO:2); Pro-Gln-Gly-Ile-Ala-Gly-Gln-D-Arg (SEQ ID NO:3); Pro-Gln-Gly-Ile-Ala-Gly-Trp (SEQ ID NO:4); Pro-Leu-Gly-Cys(Me)-His-Ala-D-Arg (SEQ ID NO:5); Pro-Leu-Gly-Met-Trp-Ser-Arg (SEQ ID NO:35); Pro-Leu-Gly-Leu-Trp-Ala-D-Arg (SEQ ID NO:6); Pro-Leu-Ala-Leu-Trp-Ala-Arg (SEQ ID NO:7); Pro-Leu-Ala-Leu-Trp-Ala-Arg (SEQ ID NO:8); Pro-Leu-Ala-Tyr-Trp-Ala-Arg (SEQ ID NO:9); Pro-Tyr-Ala-Tyr-Trp-Met-Arg (SEQ ID NO:10); Pro-Cha-Gly-Nva-His-Ala (SEQ ID NO:11); Pro-Leu-Ala-Nva (SEQ ID NO:12); Pro-Leu-Gly-Leu (SEQ ID NO:13); Pro-Leu-Gly-Ala (SEQ ID NO:14); Arg-Pro-Leu-Ala-Leu-Trp-Arg-Ser (SEQ ID NO:15); Pro-Cha-Ala-Abu-Cys(Me)-His-Ala (SEQ ID NO:16); Pro-Cha-Ala-Gly-Cys(Me)-His-Ala (SEQ ID NO:17); Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu (SEQ ID NO:18); Pro-Lys-Pro-Leu-Ala-Leu (SEQ ID NO:19); Arg-Pro-Lys-Pro-Tyr-Ala-Nva-Trp-Met (SEQ ID NO:20); Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg (SEQ ID NO:21); Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg (SEQ ID NO:22); and Arg-Pro-Lys-Pro-Leu-Ala-Nva-Trp (SEQ ID NO:23).

57. An angiogenesis inhibitor compound selected from the group consisting of

{(3R, 4S, 5S, 6R)-5-Methoxy-4-[(2R, 3R)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxy-carbonylamino}-3-methyl-but-2-enoic acid methyl ester;

- 2- $\{(3R, 4S, 5S, 6R)$ -5-Methoxy-4- $\{(2R, 3R)$ -2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonylamino $\}$ -3-methyl-butyric acid methyl ester;
- 5 2- $\{(3R, 4S, 5S, 6R)$ -5-Methoxy-4- $\{(2R, 3R)$ -2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonylamino $\}$ -4-methyl-pentanoic acid methyl ester;
- $\{(3R, 4S, 5S, 6R)$ -5-Methoxy-4- $\{(2R, 3R)$ -2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonylamino $\}$ -phenyl-acetic acid methyl ester;
- 10 (1-Carbamoyl-2-methyl-propyl)-carbamic acid- $(3R, 4S, 5S, 6R)$ -5-methoxy-4- $\{(2R, 3R)$ -2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester;
- 15 (1-Carbamoyl-2-methyl-propyl)-carbamic acid- $(3R, 4S, 5S, 6R)$ -5-methoxy-4- $\{(2R, 3R)$ -2-methyl-3-(3-methyl-butyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester;
- (1-Hydroxymethyl-2-methyl-propyl)-carbamic acid- $(3R, 4S, 5S, 6R)$ -5-methoxy-4- $\{(2R, 3R)$ -2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester;
- 20 2- $\{(3R, 4S, 5S, 6R)$ -5-Methoxy-4- $\{(2R, 3R)$ -2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonylamino $\}$ -3,3-dimethyl-butyric acid methyl ester;
- Cyclohexyl-2- $\{(3R, 4S, 5S, 6R)$ -5-Methoxy-4- $\{(2R, 3R)$ -2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonylamino $\}$ -acetic acid methyl ester;
- 25 2- $\{(3R, 4S, 5S, 6R)$ -5-Methoxy-4- $\{(2R, 3R)$ -2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonylamino $\}$ -3-methyl-pentanoic acid methyl ester;
- 30 [1-(1-Carbamoyl-2-hydroxy-ethylcarbamoyl)-2-methyl-propyl]-carbamic acid- $(3R, 4S, 5S, 6R)$ -5-methoxy-4- $\{(2R, 3R)$ -2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester;
- 2-(3- $\{(3R, 4S, 5S, 6R)$ -5-Methoxy-4- $\{(2R, 3R)$ -2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl $\}$ -ureido)-3-methyl-butyramide;
- 35 2- $\{(3R, 4S, 5S, 6R)$ -5-Methoxy-4- $\{(2R, 3R)$ -2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonylamino $\}$ -3-methyl-butyric acid;

N-Carbamoyl (ID#31) (3*R*, 4*S*, 5*S*, 6*R*) 5-methoxy-4-[(2*R*,3*R*)2-methyl-3-(3-methyl-butyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester;

- 5 N-Carbamoyl (ID#30) (3*R*, 4*S*, 5*S*, 6*R*) 5-methoxy-4-[(2*R*,3*R*)2-methyl-3-(3-methyl-butyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester;

N-Carbamoyl (ID#32) (3*R*, 4*S*, 5*S*, 6*R*) 5-methoxy-4-[(2*R*,3*R*)2-methyl-3-(3-methyl-butyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester;

- 10 N-Carbamoyl (ID#40) (3*R*, 4*S*, 5*S*, 6*R*) 5-methoxy-4-[(2*R*,3*R*)2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester;

- 15 N-Carbamoyl (ID#39) (3*R*, 4*S*, 5*S*, 6*R*) 5-methoxy-4-[(2*R*,3*R*)2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester;

N-Carbamoyl (ID#26) (3*R*, 4*S*, 5*S*, 6*R*) 5-methoxy-4-[(2*R*,3*R*)2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester;

- 20 N-Carbamoyl (ID#27) (3*R*, 4*S*, 5*S*, 6*R*) 5-methoxy-4-[(2*R*,3*R*)2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester;

- 25 (ID#24)-(2*R*-{(3*R*, 4*S*, 5*S*, 6*R*) 5-methoxy-4-[(2*R*,3*R*)2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonyl} amino-3-methyl-butanol) ester;

(ID#36)-(2*R*-{(3*R*, 4*S*, 5*S*, 6*R*) 5-methoxy-4-[(2*R*,3*R*)2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonyl} amino-3-methyl-butanol) ester;

- 30 (ID#37)-(2*R*-{(3*R*, 4*S*, 5*S*, 6*R*) 5-methoxy-4-[(2*R*,3*R*)2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonyl} amino-3-methyl-butanol) ester;

- 35 (ID#38)-(2*R*-{(3*R*, 4*S*, 5*S*, 6*R*) 5-methoxy-4-[(2*R*,3*R*)2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonyl} amino-3-methyl-butanol) ester;

(ID#34)-(2*R*-{(3*R*, 4*S*, 5*S*, 6*R*) 5-methoxy-4-[(2*R*,3*R*)2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonyl} amino-3-methyl-butanol) ester;

- 40 {2-Methyl-1-[methyl-(1-methyl-piperidin-4-yl)-carbamoyl]-propyl}-carbamic acid 5-methoxy-4-[2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester;

[1-(2-Dimethylamino-ethylcarbamoyl)-2-methyl-propyl]-carbamic acid 5-methoxy-4-[2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester;

45

{1-[(2-Dimethylamino-ethyl)-methyl-carbamoyl]-2-methyl-propyl}-carbamic acid 5-methoxy-4-[2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester;

5 [1-(3-Dimethylamino-propylcarbamoyl)-2-methyl-propyl]-carbamic acid 5-methoxy-4-[2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester;

[1-(3-Dimethylamino-2,2-dimethyl-propylcarbamoyl)-2-methyl-propyl]-carbamic acid 5-methoxy-4-[2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester;

10

[2-Methyl-1-(4-methyl-piperazine-1-carbonyl)-propyl]-carbamic acid 5-methoxy-4-[2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester;

15


{2-Methyl-1-[2-(1-methyl-pyrrolidin-2-yl)-ethylcarbamoyl]-propyl}-carbamic acid 5-methoxy-4-[2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester;

[2-Methyl-1-(4-pyrrolidin-1-yl-piperidine-1-carbonyl)-propyl]-carbamic acid 5-methoxy-4-[2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester; and

20

[1-(4-Benzyl-piperazine-1-carbonyl)-2-methyl-propyl]-carbamic acid 5-methoxy-4-[2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester.

58. A method of treating an angiogenic disease in a subject, comprising
25 administering to the subject a therapeutically effective amount of an angiogenesis inhibitor compound comprising the structure



(XV)

30 wherein

A is a MetAP-2 inhibitory core;

W is O or NR;

each R is, independently, hydrogen or alkyl;

Z is -C(O)- or -alkylene-C(O)-;

35 P is NHR, OR or a peptide consisting of one to about one hundred amino acid residues connected at the N-terminus to Z;

Q is hydrogen, linear, branched or cyclic alkyl or aryl, provided that when P is -OR, Q is not hydrogen;

or

Z is -alkylene-O- or -alkylene-N(R)-;

- 5 P is hydrogen or a peptide consisting of from one to about one hundred amino acid residues connected to Z at the carboxyl terminus;

Q is hydrogen, linear, branched or cyclic alkyl or aryl, provided that when P is hydrogen, Q is not hydrogen; and a pharmaceutically acceptable salt thereof, thereby treating the angiogenic disease in the subject.

10

59. The method of claim 58, wherein said angiogenic disease is an autoimmune disease.


15

60. The method of claim 59, wherein said autoimmune disease is rheumatoid arthritis.

61. The method of claim 58, wherein said angiogenic disease is cancer.

20

62. A method of treating an angiogenic disease in a subject, comprising administering to the subject a therapeutically effective amount of an angiogenesis inhibitor compound comprising the structure



wherein

- 25 A is a Met-AP2 inhibitory core;

W is O or NR₂;

R₁ and R₂ are each, independently, hydrogen or alkyl;

X is alkylene or substituted alkylene;

n is 0 or 1;

- 30 R₃ and R₄ are each, independently, hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl; or R₃ and R₄, together, form a ring.

together with the carbon atom to which they are attached, form a carbocyclic or heterocyclic group; or R_3 and R_4 together form an alkylene group;

Z is -C(O)- or alkylene-C(O)-; and

P is a peptide comprising from 1 to about 100 amino acid residues attached at its amino

5 terminus to Z or a group OR_5 or $N(R_6)R_7$, wherein

R_5 , R_6 and R_7 are each, independently, hydrogen, alkyl, substituted alkyl, azacycloalkyl or substituted azacycloalkyl; or R_6 and R_7 , together with the nitrogen atom to which they are attached, form a substituted or unsubstituted heterocyclic ring structure;

10 or

Z is -O-, $-NR_8-$, alkylene-O- or alkylene- NR_8- , where R_8 is hydrogen or alkyl; and

P is hydrogen, alkyl or a peptide consisting of from 1 to about 100 amino acid residues attached at its carboxy terminus to Z.

15 63. The method of claim 62, wherein said angiogenic disease is an autoimmune disease.

64. The method of claim 63, wherein said autoimmune disease is rheumatoid arthritis.

20

65. The method of claim 62, wherein said angiogenic disease is cancer.